We and others have shown that dampening KRAS signaling by targeting SHP2 may provide a tractable strategy for the treatment of cancers driven by the major (codon 12) oncogenic KRAS mutants, including non-small-cell lung cancer (NSCLC), gastroesophageal cancer, and PDAC17–22. Here, PTPN11 is linked to cancer.